Up-regulation of osteopontin expression by aryl hydrocarbon receptor via both ligand-dependent and ligand-independent pathways in lung cancer

Gene

Volumn 492, Issue 1, 2012, Pages 262-269

  Chuang, Cheng Yen ^a,b   Chang, Han ^c,d   Lin, Pinpin ^e   Sun, Shih Jung ^a   Chen, Po Hung ^a,e   Lin, Yu Ying ^a   Sheu, Gwo Tarng ^a,f   Ko, Jiunn Liang ^a,f   Hsu, Shih Lan ^b   Chang, Jinghua Tsai ^a,f  

^a CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^b TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^c CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d CHINA MEDICAL UNIVERSITY   (Taiwan)

^e NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^f CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

BaP; NFkB; Promoter assay; TCDD; Transcriptional regulation

Indexed keywords

2,3,7,8 TETRACHLORODIBENZO PARA DIOXIN; AROMATIC HYDROCARBON RECEPTOR; CIS ACTING ELEMENT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OSTEOPONTIN; XENOBIOTIC AGENT;

ARTICLE; CELL GROWTH; CELL MIGRATION; CONTROLLED STUDY; CORRELATION COEFFICIENT; DNA RESPONSIVE ELEMENT; DOWN REGULATION; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; LIGAND BINDING; LUNG CANCER; LUNG CARCINOGENESIS; PRECANCER; PRIORITY JOURNAL; PROMOTER REGION; SMOKING; TRANSCRIPTION REGULATION; UPREGULATION;

CELL LINE, TUMOR; DIOXINS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; LIGANDS; LUNG NEOPLASMS; OSTEOPONTIN; PROMOTER REGIONS, GENETIC; RECEPTORS, ARYL HYDROCARBON; RESPONSE ELEMENTS; SIGNAL TRANSDUCTION; TRANSCRIPTIONAL ACTIVATION; TRANSFECTION; UP-REGULATION;

EID: 84155189017     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2011.10.019     Document Type: Article

References (48)

1. Agrawal D., et al. Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J. Natl. Cancer Inst. 2002, 94:513-521.
2. Boffetta P., Jourenkova N., Gustavsson P. Cancer risk from occupational and environmental exposure to polycyclic aromatic hydrocarbons. Cancer Causes Control 1997, 8:444-472.
3. Boldrini L., et al. Prognostic significance of osteopontin expression in early-stage non-small-cell lung cancer. Br. J. Cancer 2005, 93:453-457.
4. Bramwell V.H., et al. Serial plasma osteopontin levels have prognostic value in metastatic breast cancer. Clin. Cancer Res. 2006, 12:3337-3343.
5. Brown L.F., et al. Osteopontin expression and distribution in human carcinomas. Am. J. Pathol. 1994, 145:610-623.
6. Chambers A.F., Wilson S.M., Kerkvliet N., O'Malley F.P., Harris J.F., Casson A.G. Osteopontin expression in lung cancer. Lung Cancer 1996, 15:311-323.
7. Chang J.T., Chang H., Chen P.H., Lin S.L., Lin P. Requirement of aryl hydrocarbon receptor overexpression for CYP1B1 up-regulation and cell growth in human lung adenocarcinomas. Clin. Cancer Res. 2007, 13:38-45.
8. Chang Y.S., Kim H.J., Chang J., Ahn C.M., Kim S.K., Kim S.K. Elevated circulating level of osteopontin is associated with advanced disease state of non-small cell lung cancer. Lung Cancer 2007, 57:373-380.
9. Cui R., et al. Abrogation of the interaction between osteopontin and alphavbeta3 integrin reduces tumor growth of human lung cancer cells in mice. Lung Cancer 2007, 57:302-310.
10. Cui R., et al. Osteopontin is involved in the formation of malignant pleural effusion in lung cancer. Lung Cancer 2009, 63:368-374.
11. Dalton T.P., Puga A., Shertzer H.G. Induction of cellular oxidative stress by aryl hydrocarbon receptor activation. Chem. Biol. Interact. 2002, 141:77-95.
12. DiNatale B.C., Schroeder J.C., Francey L.J., Kusnadi A., Perdew G.H. Mechanistic insights into the events that lead to synergistic induction of interleukin 6 transcription upon activation of the aryl hydrocarbon receptor and inflammatory signaling. J. Biol. Chem. 2010, 285:24388-24397.
13. Fong Y.C., et al. Osteopontin increases lung cancer cells migration via activation of the alphavbeta3 integrin/FAK/Akt and NF-kappaB-dependent pathway. Lung Cancer 2009, 64:263-270.
14. Frueh F.W., Hayashibara K.C., Brown P.O., Whitlock J.P. Use of cDNA microarrays to analyze dioxin-induced changes in human liver gene expression. Toxicol. Lett. 2001, 122:189-203.
15. Gotoh M., Sakamoto M., Kanetaka K., Chuuma M., Hirohashi S. Overexpression of osteopontin in hepatocellular carcinoma. Pathol. Int. 2002, 52:19-24.
16. Hoffer A., Chang C.Y., Puga A. Dioxin induces transcription of fos and jun genes by Ah receptor-dependent and -independent pathways. Toxicol. Appl. Pharmacol. 1996, 141:238-247.
17. Isa S., et al. Serum osteopontin levels are highly prognostic for survival in advanced non-small cell lung cancer: results from JMTO LC 0004. J. Thorac. Oncol. 2009, 4:1104-1110.
18. Kobayashi A., Sogawa K., Fujii-Kuriyama Y. Cooperative interaction between AhR.Arnt and Sp1 for the drug-inducible expression of CYP1A1 gene. J. Biol. Chem. 1996, 271:12310-12316.
19. Kogevinas M. Studies of cancer in humans. Food Addit. Contam. 2000, 17:317-324.
20. Kubota K., et al. Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study. Lancet Oncol. 2008, 9:1135-1142.
21. Kuznetsov N.V., et al. The dioxin/aryl hydrocarbon receptor mediates downregulation of osteopontin gene expression in a mouse model of gastric tumourigenesis. Oncogene 2005, 24:3216-3222.
22. Lai Z.W., Hundeiker C., Gleichmann E., Esser C. Cytokine gene expression during ontogeny in murine thymus on activation of the aryl hydrocarbon receptor by 2,3,7,8-tetrachlorodibenzo-p-dioxin. Mol. Pharmacol. 1997, 52:30-37.
23. Li N., Karin M. Is NF-kappaB the sensor of oxidative stress?. FASEB J. 1999, 13:1137-1143.
24. Lin P., Chang H., Ho W.L., Wu M.H., Su J.M. Association of aryl hydrocarbon receptor and cytochrome P4501B1 expressions in human non-small cell lung cancers. Lung Cancer 2003, 42:255-261.
25. Lin P., et al. Overexpression of aryl hydrocarbon receptor in human lung carcinomas. Toxicol. Pathol. 2003, 31:22-30.
26. Liu P.C., Dunlap D.Y., Matsumura F. Suppression of C/EBPalpha and induction of C/EBPbeta by 2,3,7,8-tetrachlorodibenzo-p-dioxin in mouse adipose tissue and liver. Biochem. Pharmacol. 1998, 55:1647-1655.
27. Murray G.I., et al. Tumor-specific expression of cytochrome P450 CYP1B1. Cancer Res. 1997, 57:3026-3031.
28. Osann K.E. Epidemiology of lung cancer. Curr. Opin. Pulm. Med. 1998, 4:198-204.
29. Patel R.D., Murray I.A., Flaveny C.A., Kusnadi A., Perdew G.H. Ah receptor represses acute-phase response gene expression without binding to its cognate response element. Lab. Invest. 2009, 89:695-707.
30. Pohjanvirta R., Tuomisto J. Short-term toxicity of 2,3,7,8-tetrachlorodibenzo-p-dioxin in laboratory animals: effects, mechanisms, and animal models. Pharmacol. Rev. 1994, 46:483-549.
31. Ramaiah S.K., Rittling S. Pathophysiological role of osteopontin in hepatic inflammation, toxicity, and cancer. Toxicol. Sci. 2008, 103:4-13.
32. Sarkar P., Shiizaki K., Yonemoto J., Sone H. Activation of telomerase in BeWo cells by estrogen and 2,3,7,8-tetrachlorodibenzo-p-dioxin in co-operation with c-Myc. Int. J. Oncol. 2006, 28:43-51.
33. Senger D.R., Wirth D.F., Hynes R.O. Transformed mammalian cells secrete specific proteins and phosphoproteins. Cell 1979, 16:885-893.
34. Shijubo N., et al. Vascular endothelial growth factor and osteopontin in stage I lung adenocarcinoma. Am. J. Respir. Crit. Care Med. 1999, 160:1269-1273.
35. Thalmann G.N., et al. Osteopontin: possible role in prostate cancer progression. Clin. Cancer Res. 1999, 5:2271-2277.
36. Tian Y. Ah receptor and NF-kappaB interplay on the stage of epigenome. Biochem. Pharmacol. 2009, 77:670-680.
37. Tian Y., Ke S., Denison M.S., Rabson A.B., Gallo M.A. Ah receptor and NF-kappaB interactions, a potential mechanism for dioxin toxicity. J. Biol. Chem. 1999, 274:510-515.
38. Tsuchiya Y., Nakajima M., Yokoi T. Critical enhancer region to which AhR/ARNT and Sp1 bind in the human CYP1B1 gene. J. Biochem. 2003, 133:583-592.
39. Tuck A.B., et al. Osteopontin expression in a group of lymph node negative breast cancer patients. Int. J. Cancer 1998, 79:502-508.
40. Tuck A.B., et al. Osteopontin and p53 expression are associated with tumor progression in a case of synchronous, bilateral, invasive mammary carcinomas. Arch. Pathol. Lab. Med. 1997, 121:578-584.
41. Ue T., et al. Co-expression of osteopontin and CD44v9 in gastric cancer. Int. J. Cancer 1998, 79:127-132.
42. Vogel C., Abel J. Effect of 2,3,7,8-tetrachlorodibenzo-p-dioxin on growth factor expression in the human breast cancer cell line MCF-7. Arch. Toxicol. 1995, 69:259-265.
43. Wai P.Y., Kuo P.C. Osteopontin: regulation in tumor metastasis. Cancer Metastasis Rev. 2008, 27:103-118.
44. Wang C.K., et al. Aryl hydrocarbon receptor activation and overexpression upregulated fibroblast growth factor-9 in human lung adenocarcinomas. Int. J. Cancer 2009, 125:807-815.
45. Weber G.F., Ashkar S., Glimcher M.J., Cantor H. Receptor-ligand interaction between CD44 and osteopontin (Eta-1). Science 1996, 271:509-512.
46. Weiss C., et al. TCDD induces c-jun expression via a novel Ah (dioxin) receptor-mediated p38-MAPK-dependent pathway. Oncogene 2005, 24:4975-4983.
47. Wejheden C., Brunnberg S., Hanberg A., Lind P.M. Osteopontin: a rapid and sensitive response to dioxin exposure in the osteoblastic cell line UMR-106. Biochem. Biophys. Res. Commun. 2006, 341:116-120.
48. Wu C.Y., et al. Elevated plasma osteopontin associated with gastric cancer development, invasion and survival. Gut 2007, 56:782-789.